01. Doctor Overview
Dr. Brian W. Loggie currently serves as a professor of surgery at Creighton University School of Medicine located in Omaha, Nebraska and is chief of the division of surgical oncology and director of the Cancer Biology Program at Creighton University Medical Center. Prior to assuming his leadership roles at Creighton in 2002, Dr. Loggie held faculty positions at the University of Illinois at Chicago, the Bowman Gray School of Medicine in Winston-Salem, North Carolina and the University of Texas Southwestern Medical Center in Dallas, Texas.
Dr. Loggie is internationally-renowned for his expertise and clinical experience in treating cancers that are metastatic to or that have originated in the peritoneal lining (thin tissue layer) of the abdomen and pelvis. He is a pioneer in the use of hyperthermic intraperitoneal chemotherapy (HIPEC) treatment for peritoneal mesothelioma. Dr. Loggie has assembled a clinical and translational research team at Creighton with a particular focus on identifying innovative and more effective treatments for malignant peritoneal mesothelioma and pseudomyxoma peritonei (PMP), a rare and slow-growing form of cancer that usually originates in the appendix or ovaries.
Dr. Loggie has coauthored several scientific, peer-reviewed articles that have been published in such journals as The American Surgeon, the Journal of Surgical Oncology, World Journal of Surgical Oncology, Annals of Surgical Oncology, among others.
02. Fast Facts
Doctor Fast Facts
Main Specialty: Surgery, Oncology
Other Interests & Specialties: Metastatic cancers, cancer originating in the peritoneal lining of the abdomen and pelvis, hyperthermic intraperitoneal, chemotherapy (HIPEC) treatment, surgical oncology, peritoneal mesothelioma, peritoneal carcinomatosis, malignant ascites, cutaneous malignant melanoma, pseudomyxoma peritonei, abdominopelvic and retroperitoneal sarcomas, management of complex primary or recurrent solid tumors, peritoneal neoplastic disease, appendix neoplasms, gastrointestinal cancers, ovarian cancers, estrogen receptor regulation and clinical trials for mesothelioma.
Certifications, Awards & Accolades: Royal College of Surgeons of Canada fellow, Society of Surgical Oncology fellow, American College of Surgeons fellow, Southeastern Surgical Congress fellow, Canadian Association of General Surgeons member, Association for Academic Surgery member, American Medical Association member, Southern Association for Oncology member, American Society of Clinical Oncology member, named one of the Best Doctors in America, Magis Award from Creighton University, named one of Castle Connolly’s America’s Top Doctors
Education & Experience:
- Bachelor of Science at Loyola College
- Medical Degree from McGill University
- Residency at Montreal General Hospital
- Fellowship at University of Illinois
Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma. The American Surgeon. April 2014;80(4):348-52.
Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. World Journal of Surgical Oncology. October 2010;13(8):88. doi: 10.1186/1477-7819-8-88
Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma. Annals of Surgical Oncology. January 2009;16(1):152-8. doi: 10.1245/s10434-008-0206-6